NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMediumNegative
Announced Tue, 17 Jun · 19:44 IST

Disclosure under Regulation 30 of SEBI Listing Regulations

Insider Trading ChargeRegulatory & Legal View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Neuland Laboratories has disclosed that its Compliance Officer received an administrative warning letter from the Deputy General Manager of SEBI dated June 13, 2025 (received on June 17, 2025). The warning relates to a violation of SEBI's Prohibition of Insider Trading (PIT) Regulations, specifically a pre-clearance requirement breach by a designated person of the company. The company has clarified that there is no material impact on its financials, operations, or other activities.

Likely market impact

This is an administrative warning rather than a formal penalty, and the company states there is no material impact. However, it does highlight a compliance lapse in insider trading norms which may be viewed negatively by the market and could attract further regulatory scrutiny if not addressed.